- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04822025
A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Elderly Adults
A Phase II, Prospective, Randomized, Double-Blind, Dose-Comparison, Multi-Center Study to Evaluate the Safety, Tolerability, and Immunogenicity of the SARS-CoV-2 Vaccine Candidate MVC-COV1901 in Elderly Adults
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Hualien City, Taiwan
- Hualien Tzu Chi Hospital
-
New Taipei City, Taiwan
- Shuang H Hospital
-
Taipei, Taiwan
- National Taiwan University Hospital
-
Taoyuan, Taiwan
- Chang Gung Medical Hospital Linkou
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female participant ≥ 65 years of age at randomization.
- Healthy adults or adults with pre-existing medical conditions who are in stable condition. A stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease 3 months before enrollment and expected to remain stable for the duration of the study.
- Participant is willing and able to comply with all required study visits and follow-up required by this protocol.
- Participant has not travelled overseas within 14 days of screening and will not have any oversea traveling throughout the study period.
- Participant is able to understand and comply with study requirements/procedures (if applicable, with assistance by caregiver, surrogate, or legally authorized representative) based on the assessment of the investigator and must provide written informed consent.
Exclusion Criteria:
- Employees at the investigator's site, of the Sponsor or the contract research organization (CRO) who are directly involved in the conduct of the study.
- Currently receiving or received any investigational intervention within 30 days prior to the first dose of study intervention.
- Administered any licensed live-attenuated vaccines within 28 days or other licensed non-live-attenuated vaccines within 7 days prior to the first dose of study intervention.
- Administered any blood product or intravenous (IV) immunoglobulin administration within 12 weeks prior to the first dose of study intervention.
- Participant previously received any coronavirus vaccine.
- Currently receiving or anticipate to receive concomitant immunosuppressive or immune-modifying therapy (excluding inhaled, topical skin and/or eye drop-containing corticosteroids, low-dose methotrexate, or < 2 weeks of daily receipt of prednisone less than 20 mg or equivalent) within 12 weeks prior to the first dose of study intervention.
- Currently receiving or anticipate to receive treatment with tumor necrosis factor (TNF)-α inhibitors, e.g. infliximab, adalimumab, etanercept within 12 weeks prior to the first dose of study intervention.
- Major surgery or any radiation therapy within 12 weeks prior to the first dose of study intervention.
- Immunosuppressive illness or immunodeficient state, including hematologic malignancy, history of solid organ, bone marrow transplantation, or asplenia.
- A history of malignancy with potential risk for recurrence after curative treatment, or current diagnosis of or treatment for cancer (exceptions are squamous and basal cell carcinomas of the skin and treated uterine cervical carcinoma in situ, at the discretion of the investigator).
- Bleeding disorder considered a contraindication to intramuscular injection or phlebotomy.
- Participant with known human immunodeficiency virus (HIV) infection or who is HIV antibody positive, with CD4 count < 350 cells/mm3 or a detectable HIV viral load within the past year (low level variations from 50-500 viral copies/mL or equivalent which do not lead to changes in antiretroviral therapy [ART] are permitted).
- Participant who, in the investigator's judgement, is not in stable condition and by participating in the study could adversely affect the safety of the participant, interfere with adherence to study requirements or evaluation of any study endpoint. This may include aparticipant with ongoing acute diseases, severe infections, autoimmune disease, laboratory abnormality or serious medical conditions in the following systems: cardiovascular, pulmonary, hepatic, neurologic, metabolic, renal, or psychiatric.
- Participant with previous known SARS-CoV-1 or 2 infection or potential exposure to SARS-CoV-1 or 2 viruses (EXCEPT for those who have been tested negative or completed the self-managements/ home quarantines/ home isolations)
- Participant with a history of hypersensitivity to any vaccine or a history of allergic disease or reactions likely to be exacerbated by any component of the MVC-COV1901.
- Body (oral, rectal, or ear) temperature ≥ 38.0°C or acute illness (not including minor illnesses such as diarrhea or mild upper respiratory tract infection at the discretion of the investigator) within 2 days before the first dose of study intervention.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: High Dose
High-Dose S-2P protein with CpG and Aluminum Hydroxide/0.5mL
|
Approximately 300 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region
|
Experimental: Mid Dose
Mid-Dose S-2P protein with CpG and Aluminum Hydroxide/0.5mL
|
Approximately 100 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Adverse Events(AEs) [Safety and Tolerability]
Time Frame: Day 1 to 28 days after the second vaccination
|
To evaluate the incidence of Adverse Events(AEs) of MVC-COV1901 from Visit 2 (Day 1) to Visit 6 (28 days after the second dose of study intervention) in terms of the number and percentage of participants with the occurrence of: Solicited local AEs (up to 7 days after each dose of study intervention) Solicited systemic AEs (up to 7 days after each dose of study intervention) Unsolicited AEs (up to 28 days after each dose of study intervention) AE of Special Interest (AESI) Vaccine-Associated Enhanced Disease(VAED) Serious adverse events (SAEs) |
Day 1 to 28 days after the second vaccination
|
Immunogenicity of MVC-COV1901
Time Frame: Day 1 to 28 days after the second vaccination
|
To evaluate the immunogenicity of High-dose MVC-COV1901, as compared to Mid-dose MVC-COV1901, in terms of neutralizing antibody titers.
|
Day 1 to 28 days after the second vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Adverse Events(AEs) [Safety and Tolerability]
Time Frame: Day 1 to 180 days after the second vaccination
|
To evaluate the Incidence of Adverse Events(AEs) of MVC-COV1901 over the study period in terms of the number and percentage of participants with the occurrence of: >= Grade 3 AE AE of Special Interest (AESI) Vaccine-Associated Enhanced Disease(VAED) Serious adverse events (SAEs) |
Day 1 to 180 days after the second vaccination
|
Immunogenicity of MVC-COV1901
Time Frame: Day 1 to 180 days after the second vaccination
|
The antigen-specific immunoglobulin titers and neutralizing antibody titers at Visit 4 (28 days after the first dose of study intervention), Visit 6 (28 days after the second dose of study intervention), Visit 7 (90 days after the second dose of study intervention) and Visit 8 (180 days after the second dose of study intervention) in terms of antigen-specific immunoglobulin titers and neutralizing antibody titers
|
Day 1 to 180 days after the second vaccination
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CT-COV-23
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19 Vaccine
-
Gamaleya Research Institute of Epidemiology and...Moscow Healthcare DepartmentRecruitingCovid19 | Vaccine Preventable DiseaseRussian Federation
-
National University Hospital, SingaporeAgency for Science, Technology and Research; National University of SingaporeUnknownCovid19 | Breastfeeding | Vaccine Exposure Via Breast MilkSingapore
-
Xavier University of Louisiana.CompletedCovid19 | Vaccine Hesitancy | Vaccine RefusalUnited States
-
Masaryk UniversityRecruitingAdverse Reaction to Vaccine | COVID19 VaccinePoland, Canada, United States, Croatia, Czechia, Estonia, Ethiopia, Germany, Ghana, Mexico, Portugal, Russian Federation, Serbia, Slovenia
-
Rajavithi HospitalDepartment of Medical servicesWithdrawnCovid19 | Covid19 Vaccine
-
Stanford UniversityActive, not recruitingVaccine Hesitancy | Vaccine Refusal | Vaccine KnowledgeKenya
-
Children's Mercy Hospital Kansas CityCompletedVaccine Hesitancy | Vaccine RefusalUnited States
-
University of OttawaNot yet recruitingPneumococcal Vaccine Uptake | Vaccination Willingness | Pneumococcal Vaccine Knowledge | Pneumococcal Vaccine AttitudeCanada
-
PT Bio FarmaCenter for Child Health Universitas Gadjah Mada (CCH-PRO UGM; Cipto Mangunkusumo... and other collaboratorsRecruitingVaccine Adverse Reaction | Vaccine ReactionIndonesia
-
Indiana UniversityMerck Sharp & Dohme LLCCompletedHPV Vaccine Attitudes | HPV Vaccine IntentionUnited States
Clinical Trials on MVC-COV1901 (High-Dose)
-
Medigen Vaccine Biologics Corp.Coalition for Epidemic Preparedness InnovationsCompleted
-
Taoyuan General HospitalMedigen Vaccine Biologics Corp.Recruiting
-
Medigen Vaccine Biologics Corp.Completed
-
Medigen Vaccine Biologics Corp.Completed
-
Medigen Vaccine Biologics Corp.Completed
-
Medigen Vaccine Biologics Corp.CompletedCOVID-19 VaccineParaguay
-
Medigen Vaccine Biologics Corp.Completed
-
Chang Gung Memorial HospitalMedigen Vaccine Biologics Corp.Active, not recruitingCOVID-19 | Breakthrough InfectionTaiwan
-
Medigen Vaccine Biologics Corp.Completed
-
Medigen Vaccine Biologics Corp.CompletedCovid19 VaccineTaiwan, Vietnam